查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1620832

再生医学市场：按类型、应用分类 - 2025-2030 年全球预测

Regenerative Medicine Market by Type (Cell-Based Immunotherapy & Cell Therapy Products, Gene Therapy Products, Small Molecule & Biologic), Application (Cardiovascular, Diabetes, Musculoskeletal Disorders) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年再生医学市场价值为230.2亿美元，预计2024年将达到283.5亿美元，复合年增长率为23.76%，到2030年将达到1024亿美元。

再生医学是一个变革性的医疗保健领域，专注于利用干细胞疗法、组织工程和基因编辑等技术来修復、替换和再生受损的组织和器官。这种需求源自于慢性病的增加、人口老化以及传统医学治疗的限制。应用范围广泛，包括整形外科、皮肤科、心臟科和神经病学。最终用途领域从医院和诊所到研究机构和生技公司，凸显了市场潜力的广泛性。市场成长受到多种因素的影响，包括生物技术和材料科学的进步、政府和私人资金的增加以及再生疗法意识的增强。潜在的商机在于未开发的新兴市场、持续的研发以及主要企业之间的策略联盟。

主要市场统计
基准年[2023] 230.2亿美元
预测年份 [2024] 283.5亿美元
预测年份 [2030] 1024亿美元
复合年增长率（%） 23.76%

然而，这个市场也存在局限性和挑战，包括不断上升的治疗成本、严格的法律规范、围绕干细胞使用的伦理问题以及扩大生产的技术障碍。也存在治疗方法标准化、治疗效果延长等问题。为了推动业务成长，在开发具有成本效益的生物加工技术、利用人工智慧和机器学习进行个人化医疗以及增强组织工程的支架材料方面存在创新机会。此外，专注于非侵入性再生治疗并创建用于治疗监测的可靠生物标记也可能是一条有利的途径。

竞争格局正在迅速变化，需要不断的创新和策略远见。公司应该透过投资跨学科合作和伙伴关係以及交叉传播思想和技术来保持创新曲线的领先地位。由于技术创新和解决未满足的需求的双重力量，该市场有望大幅扩张。如果我们能够明智地管理这些复杂的动态，我们相信我们将能够在市场上建立牢固的地位，并为全球医疗保健的发展做出重大贡献。

市场动态：揭示快速发展的再生医学市场的关键市场洞察

供需的动态交互作用正在改变再生医学市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 扩大干细胞技术、基因治疗和组织工程的应用
    • 政府研究投入增加
    • 私人公司的产品核可和研发活动的活性化
  • 市场限制因素
    • 与干细胞和再生医学相关的高成本和监管问题
  • 市场机会
    • 再生医学生技药品的技术进步
    • 对器官和骨移植的需求不断增加
  • 市场挑战
    • 有关在研究和开发中使用胚胎干细胞的伦理问题

波特五力：驾驭再生医学市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解再生医学市场的外部影响

外部宏观环境因素在塑造再生医学市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解再生医学市场的竞争状况

对再生医学市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵再生医学市场供应商绩效评估

FPNV定位矩阵是评估再生医学市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了再生医学市场的成功之路

再生医学市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开发：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、未开发地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 更多采用干细胞技术、基因治疗和组织工程
      • 政府加大对再生医学研究的投资
      • 产品核可以及私人公司研发活动的增加
    • 抑制因素
      • 与干细胞和再生医学相关的高成本和监管问题
    • 机会
      • 再生医学生技药品的技术进步
      • 对器官和骨移植的需求增加
    • 任务
      • 有关在研究和开发中使用胚胎干细胞的伦理问题
  • 市场区隔分析
    • 类型：细胞免疫疗法和细胞治疗产品在个人化治疗中的重要应用
    • 应用：再生医学在心血管疾病的重要性日益增加
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章再生医学市场：依类型

  • 基于细胞的免疫疗法和细胞治疗产品
    • 同类产品
    • 自製产品
  • 基因治疗产品
  • 小分子/生技药品
  • 组织工程产品

第七章再生医学市场：依应用分类

  • 心血管
  • 糖尿病
  • 肌肉骨骼疾病
  • 眼科疾病
  • 肿瘤学
  • 创伤护理

第八章 北美和南美再生医学市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太地区再生医学市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章欧洲、中东、非洲再生医学市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • 4DMT 的 4D-150 获得 FDA 的高级治疗指定，这是一种用于玻璃体内治疗湿性 AMD 的基因药物。
    • Sysmex 和 JCR Pharma 的合资企业 Allied Cell 收购了一条新的管道，以促进再生医疗产品的早期社会实施
    • 西乃山建立再生医学研究所
  • 战略分析和建议

公司名单

  • 4D Molecular Therapeutics, Inc.
  • Allergan PLC
  • Amgen Inc.
  • Astellas Pharma Inc.
  • Athersys, Inc.
  • Bayer AG
  • CMIC HOLDINGS Co., LTD.
  • Editas Medicine, Inc.
  • FUJIFILM Cellular Dynamics, Inc.
  • Gilead Sciences, Inc.
  • Integra LifeSciences Holdings Corporation
  • JCR Pharmaceuticals Co., Ltd.
  • Medtronic PLC
  • Mimedx Group
  • Novartis AG
  • Organogenesis Inc.
  • Osiris Therapeutics, Inc. by Smith & Nephew PLC
  • REPROCELL Inc.
  • SanBio Company Limited
  • Sartorius AG
  • Sumitomo Pharma Co., Ltd.
  • Sysmex Corporation
  • Takeda Pharmaceutical Co. Ltd.
  • Tenaya Therapeutics, Inc.
  • Vericel Corporation
  • Wright Medical Group NV
  • Zimmer Biomet Holdings Inc.
Product Code: MRR-430D42AA0F5B

The Regenerative Medicine Market was valued at USD 23.02 billion in 2023, expected to reach USD 28.35 billion in 2024, and is projected to grow at a CAGR of 23.76%, to USD 102.40 billion by 2030.

Regenerative medicine is a transformative healthcare arena focused on repairing, replacing, or regenerating damaged tissues and organs using techniques like stem cell therapy, tissue engineering, and gene editing. Its necessity arises from the increasing prevalence of chronic diseases, aging populations, and the limitations of conventional medical therapies. Applications are vast, spanning orthopedics, dermatology, cardiology, and neurology, among others. End-use sectors range from hospitals and clinics to research institutions and biotech companies, highlighting its broad market potential. The market growth is influenced by several factors: advancements in biotechnology and material science, an increase in government and private funding, and rising awareness about regenerative treatments. Potential opportunities lie in untapped emerging markets, continual R&D, and strategic collaborations among key industry players.

KEY MARKET STATISTICS
Base Year [2023] USD 23.02 billion
Estimated Year [2024] USD 28.35 billion
Forecast Year [2030] USD 102.40 billion
CAGR (%) 23.76%

However, limitations and challenges in this market include high costs of treatment, stringent regulatory frameworks, ethical concerns associated with stem cell use, and technical hurdles in scaling production. The sector also faces challenges related to the standardization of therapies and the long-time horizon for treatment efficacy. To foster business growth, innovation opportunities exist in developing cost-effective bioprocessing techniques, leveraging AI and machine learning for personalized medicine, and enhancing scaffolding materials for tissue engineering. Additionally, focusing on non-invasive regenerative therapies and creating reliable biomarkers for treatment monitoring could present lucrative avenues.

The regenerative medicine market is characterized by intense research and a rapidly evolving competitive landscape, necessitating constant technological advancements and strategic foresight. Companies should invest in interdisciplinary collaborations and partnerships to cross-pollinate ideas and technologies, thereby staying ahead in the innovation curve. This market is poised for significant expansion, driven by the dual forces of innovation and the unmet clinical needs it seeks to address. Those navigating these intricate dynamics wisely are likely to achieve robust market positions and contribute meaningfully to the advancement of global healthcare.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Regenerative Medicine Market

The Regenerative Medicine Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing adoption of stem cell technologies, gene therapies, and tissue engineering
    • Rising government investments in regenerative medicine research
    • Product approval coupled with increasing R&D activities by private players
  • Market Restraints
    • High cost and regulatory issues pertaining to stem cell and regenerative medicine
  • Market Opportunities
    • Technological advancements in regenerative medicine biologics
    • Growing demand for organ transplantation and bone grafting
  • Market Challenges
    • Ethical issues related to the use of embryonic stem cells in R&D

Porter's Five Forces: A Strategic Tool for Navigating the Regenerative Medicine Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Regenerative Medicine Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Regenerative Medicine Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Regenerative Medicine Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Regenerative Medicine Market

A detailed market share analysis in the Regenerative Medicine Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Regenerative Medicine Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Regenerative Medicine Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Regenerative Medicine Market

A strategic analysis of the Regenerative Medicine Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Regenerative Medicine Market, highlighting leading vendors and their innovative profiles. These include 4D Molecular Therapeutics, Inc., Allergan PLC, Amgen Inc., Astellas Pharma Inc., Athersys, Inc., Bayer AG, CMIC HOLDINGS Co., LTD., Editas Medicine, Inc., FUJIFILM Cellular Dynamics, Inc., Gilead Sciences, Inc., Integra LifeSciences Holdings Corporation, JCR Pharmaceuticals Co., Ltd., Medtronic PLC, Mimedx Group, Novartis AG, Organogenesis Inc., Osiris Therapeutics, Inc. by Smith & Nephew PLC, REPROCELL Inc., SanBio Company Limited, Sartorius AG, Sumitomo Pharma Co., Ltd., Sysmex Corporation, Takeda Pharmaceutical Co. Ltd., Tenaya Therapeutics, Inc., Vericel Corporation, Wright Medical Group N.V., and Zimmer Biomet Holdings Inc..

Market Segmentation & Coverage

This research report categorizes the Regenerative Medicine Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Cell-Based Immunotherapy & Cell Therapy Products, Gene Therapy Products, Small Molecule & Biologic, and Tissue-Engineered Products. The Cell-Based Immunotherapy & Cell Therapy Products is further studied across Allogeneic Products and Autologous Products.
  • Based on Application, market is studied across Cardiovascular, Diabetes, Musculoskeletal Disorders, Ocular Disorders, Oncology, and Wound Care.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing adoption of stem cell technologies, gene therapies, and tissue engineering
      • 5.1.1.2. Rising government investments in regenerative medicine research
      • 5.1.1.3. Product approval coupled with increasing R&D activities by private players
    • 5.1.2. Restraints
      • 5.1.2.1. High cost and regulatory issues pertaining to stem cell and regenerative medicine
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements in regenerative medicine biologics
      • 5.1.3.2. Growing demand for organ transplantation and bone grafting
    • 5.1.4. Challenges
      • 5.1.4.1. Ethical issues related to the use of embryonic stem cells in R&D
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Significant applications of cell-based immunotherapies and cell therapy products in personalized treatment
    • 5.2.2. Application: Growing significance of regenerative medicines for cardiovascular diseases
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Regenerative Medicine Market, by Type

  • 6.1. Introduction
  • 6.2. Cell-Based Immunotherapy & Cell Therapy Products
    • 6.2.1. Allogeneic Products
    • 6.2.2. Autologous Products
  • 6.3. Gene Therapy Products
  • 6.4. Small Molecule & Biologic
  • 6.5. Tissue-Engineered Products

7. Regenerative Medicine Market, by Application

  • 7.1. Introduction
  • 7.2. Cardiovascular
  • 7.3. Diabetes
  • 7.4. Musculoskeletal Disorders
  • 7.5. Ocular Disorders
  • 7.6. Oncology
  • 7.7. Wound Care

8. Americas Regenerative Medicine Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Regenerative Medicine Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Regenerative Medicine Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
    • 11.3.1. 4DMT Receives FDA Regenerative Medicine Advanced Therapy Designation for 4D-150 Genetic Medicine for Intravitreal Treatment of Wet AMD
    • 11.3.2. AlliedCel, a Joint Venture Between Sysmex and JCR Pharmaceuticals, Has Acquired a New Pipeline to Promote the Early Social Implementation of Regenerative Medicine Products
    • 11.3.3. Mount Sinai Launches Institute for Regenerative Medicine
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. 4D Molecular Therapeutics, Inc.
  • 2. Allergan PLC
  • 3. Amgen Inc.
  • 4. Astellas Pharma Inc.
  • 5. Athersys, Inc.
  • 6. Bayer AG
  • 7. CMIC HOLDINGS Co., LTD.
  • 8. Editas Medicine, Inc.
  • 9. FUJIFILM Cellular Dynamics, Inc.
  • 10. Gilead Sciences, Inc.
  • 11. Integra LifeSciences Holdings Corporation
  • 12. JCR Pharmaceuticals Co., Ltd.
  • 13. Medtronic PLC
  • 14. Mimedx Group
  • 15. Novartis AG
  • 16. Organogenesis Inc.
  • 17. Osiris Therapeutics, Inc. by Smith & Nephew PLC
  • 18. REPROCELL Inc.
  • 19. SanBio Company Limited
  • 20. Sartorius AG
  • 21. Sumitomo Pharma Co., Ltd.
  • 22. Sysmex Corporation
  • 23. Takeda Pharmaceutical Co. Ltd.
  • 24. Tenaya Therapeutics, Inc.
  • 25. Vericel Corporation
  • 26. Wright Medical Group N.V.
  • 27. Zimmer Biomet Holdings Inc.

LIST OF FIGURES

  • FIGURE 1. REGENERATIVE MEDICINE MARKET RESEARCH PROCESS
  • FIGURE 2. REGENERATIVE MEDICINE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. REGENERATIVE MEDICINE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. REGENERATIVE MEDICINE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. REGENERATIVE MEDICINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. REGENERATIVE MEDICINE MARKET DYNAMICS
  • TABLE 7. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY ALLOGENEIC PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY AUTOLOGOUS PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY SMALL MOLECULE & BIOLOGIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE-ENGINEERED PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY OCULAR DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY WOUND CARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 48. AUSTRALIA REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 51. CHINA REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 54. INDIA REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 57. INDONESIA REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 60. JAPAN REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 63. MALAYSIA REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 66. PHILIPPINES REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 69. SINGAPORE REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 72. SOUTH KOREA REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 75. TAIWAN REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 78. THAILAND REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 81. VIETNAM REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 88. DENMARK REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 91. EGYPT REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 94. FINLAND REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 97. FRANCE REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 100. GERMANY REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 103. ISRAEL REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 106. ITALY REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 109. NETHERLANDS REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 112. NIGERIA REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 115. NORWAY REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 118. POLAND REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 121. QATAR REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 124. RUSSIA REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 127. SAUDI ARABIA REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH AFRICA REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 133. SPAIN REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 136. SWEDEN REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 139. SWITZERLAND REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 142. TURKEY REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED ARAB EMIRATES REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED KINGDOM REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 149. REGENERATIVE MEDICINE MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 150. REGENERATIVE MEDICINE MARKET, FPNV POSITIONING MATRIX, 2023